Pharmaceutical

AbbVie and FutureGen link on inflammatory bowel disease

AbbVie has made a licence agreement with FutureGen Biopharmaceutical for developing FG-M701 for inflammatory bowel disease (IBD).

Jun 16, 2024 - 04:00
AbbVie and FutureGen link on inflammatory bowel disease
AbbVie has made a licence agreement with FutureGen Biopharmaceutical for developing FG-M701 for inflammatory bowel disease (IBD).
Read the original article

Tags:

Previous Article

Suven Pharmaceuticals to gain controlling stake in Sapala Organics

Next Article

UK’s new Netflix-style funding model for antibiotics goes live

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

In absence of Roe v. Wade, an abortion doctor dwells on all the patients she does not see

In absence of Roe v. Wade, an abortion doctor dwells on...

Jun 24, 2023

Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023

Revenue growth for 13 of top 20 biopharmas with obesity...

Aug 1, 2024

Opinion: Hospices can’t handle the growing number of patients who need wound care

Opinion: Hospices can’t handle the growing number of pa...

Nov 25, 2023